Login to Your Account



Pharma: Clinic Roundup


Wednesday, February 22, 2012
• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, reported top-line results from the GEMINI I Phase III study of vedolizumab in 895 patients with moderately to severely active ulcerative colitis who have failed at least one conventional therapy, including tumor necrosis factor-alpha antagonists. Both phases of the year-long trial met their primary endpoints, providing statistically significant improvements in clinical response in the six-week induction phase and clinical remission in the subsequent maintenance phase.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription